Breaking News Instant updates and real-time market news.

ARIA

Acquired by TKPYY 2/17

$13.70

-0.455 (-3.22%)

07:37
11/29/16
11/29
07:37
11/29/16
07:37

ARIAD announces FDA full approval, label update for Iclusig

ARIAD announced that the U.S. Food and Drug Administration has granted Iclusig full approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia for whom no other tyrosine kinase inhibitor therapy is indicated; and for the treatment of adult patients with T315I-positive CML or T315I positive Ph+ ALL. Iclusig was initially approved in December 2012 under the FDA's accelerated approval program, which provides patients earlier access to promising new drugs that treat serious conditions based on a surrogate endpoint while the company conducts additional studies to confirm the drug's clinical benefit. The therapy was granted the FDA's orphan drug designation because it is intended to treat a rare disease or condition. This full approval and label update is based on 48-month follow-up data from the pivotal Phase 2 PACE clinical trial of Iclusig in heavily pretreated patients with resistant or intolerant CML or Ph+ ALL. These data were presented at the 2016 meetings of the American Society for Clinical Oncology and the European Hematology Association.

  • 03

    Dec

  • 04

    Dec

  • 29

    Apr

ARIA Acquired by TKPYY 2/17
$13.70

-0.455 (-3.22%)

10/26/16
WBLR
10/26/16
NO CHANGE
Target $15
WBLR
Outperform
Unfazed by congressional inquiry, William Blair ups ARIAD target to $15
William Blair analyst Y. Katherine Xu raised her price target for ARIAD Pharmaceuticals to $15 from $12 on higher sales expectations. The analyst upped her peak global sales forecast of Iclusig to $1.1B from $900M, based on projected increased second-line uptake in 2019 and beyond. Xu also increased her estimate for global peak sales of brigatinib to $790M from $640M, based on a competitive profile analysis after the European Society of Medical Oncology meeting. Her model values Iclusig in chronic myelogenous leukemia at $9 per share and brigatinib at $6 per share, with a 90% probability of success in ALK+ non-small-cell lung cancer. Xu keeps an Outperform rating on shares of ARIAD. She believes the recent congressional inquiry on Iclusig pricing is unlikely to affect her peak sales estimates. ARIAD remains an attractive takeout candidate in the 2017-2018 timeframe "given the pending brigatinib approval and the strength of the portfolio," Xu tells investors in a research note. ARIAD in pre-market trading is up 14c to $9.48.
10/26/16
JEFF
10/26/16
NO CHANGE
Target $11
JEFF
Buy
ARIAD price target lowered to $11 from $13 at Jefferies
Jefferies analyst Eun Yang lowered her price target for ARIAD Pharmaceuticals to $11 following the recent scrutiny on Iclusig pricing. Iclusig's pricing scheme "has been overly aggressive," but there is a "clear therapeutic value" to the drug, Yang tells investors in a research note. She believes the company will likely need to modify its pricing strategy. Yang lowered her sales estimates by 23% in 2017 and beyond but keeps a Buy rating on ARIAD. William Blair this morning raised its price target for the shares to $15 from $12.
11/03/16
DBAB
11/03/16
INITIATION
Target $9.5
DBAB
Hold
ARIAD initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Andrew Peters started ARIAD Pharmaceuticals with a Hold rating and $9.50 price target. Headline risk from pricing could overshadow any positive pipeline news flow until the issue is resolved, Peters tells investors in a research note. He expects the stock to be range-bound in the near-term.
11/03/16
11/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BioMarin (BMRN) initiated with a Buy at Deutsche Bank. 2. Ambev (ABEV) reinstated with an Equal Weight at Barclays. 3. ARIAD (ARIA) initiated with a Hold at Deutsche Bank. 4. Thomson Reuters (TRI) reinstated with a Neutral at JPMorgan. 5. Exelixis (EXEL) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage click here.

TODAY'S FREE FLY STORIES

AAN

Aaron's

$38.83

-0.39 (-0.99%)

17:19
09/21/17
09/21
17:19
09/21/17
17:19
Hot Stocks
Aaron's provides update on impact of Hurricane Irma »

Aaron's plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDC

M.D.C. Holdings

$31.73

0.11 (0.35%)

17:10
09/21/17
09/21
17:10
09/21/17
17:10
Hot Stocks
M.D.C. Holdings announces Richmond American Homes enters Oregon Market »

M.D.C. Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

17:09
09/21/17
09/21
17:09
09/21/17
17:09
Hot Stocks
Versartis down 85% after Phase 3 of somavaratan did not meet primary endpoint »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IART

Integra LifeSciences

$48.31

-0.58 (-1.19%)

17:05
09/21/17
09/21
17:05
09/21/17
17:05
Hot Stocks
Integra LifeSciences enrolls first patient in Cadence ankle system study »

Integra LifeSciences has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TIF

Tiffany

$89.85

-0.08 (-0.09%)

, RL

Ralph Lauren

$88.48

-0.63 (-0.71%)

17:04
09/21/17
09/21
17:04
09/21/17
17:04
Hot Stocks
Tiffany names Roger Farah as Chairman of Board, effective October 2 »

Tiffany & Co. (TIF)…

TIF

Tiffany

$89.85

-0.08 (-0.09%)

RL

Ralph Lauren

$88.48

-0.63 (-0.71%)

M

Macy's

$21.16

-0.32 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

VSAR

Versartis

$21.60

-0.25 (-1.14%)

17:00
09/21/17
09/21
17:00
09/21/17
17:00
Hot Stocks
Breaking Hot Stocks news story on Versartis 

Versartis trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLS

Flowserve

$42.19

-0.19 (-0.45%)

16:57
09/21/17
09/21
16:57
09/21/17
16:57
Hot Stocks
Flowserve appoints Lee Eckert as CFO »

Flowserve has named Lee…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIG

AIG

$60.50

0.38 (0.63%)

16:57
09/21/17
09/21
16:57
09/21/17
16:57
Periodicals
Regulators weigh removing SIFI 'tag' from insurer AIG, Dow Jones says »

According to the report,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$34.94

-0.06 (-0.17%)

16:54
09/21/17
09/21
16:54
09/21/17
16:54
Hot Stocks
Aecom announces capital allocation policy and $1B stock repurchase authorization »

Aecom announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALOG

Analogic

$79.95

2.35 (3.03%)

16:49
09/21/17
09/21
16:49
09/21/17
16:49
Hot Stocks
Analogic achieves ECAC standard C2 for new cabin baggage screening solution »

Analogic announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMP

Compass Minerals

$69.50

-0.45 (-0.64%)

16:39
09/21/17
09/21
16:39
09/21/17
16:39
Earnings
Compass Minerals lowers FY17 EPS view to $2.50-$2.80 from $3.00-$3.50 »

Consensus is $3.02. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 29

    Sep

MDU

MDU Resources

$26.21

-0.19 (-0.72%)

16:39
09/21/17
09/21
16:39
09/21/17
16:39
Hot Stocks
MDU Resources names Jason Vollmer CFO, Stephanie Barth CAO »

MDU Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:36
09/21/17
09/21
16:36
09/21/17
16:36
General news
Money Supply M2 Weekly Change data reported »

Week of 9/11 Money Supply…

16:36
09/21/17
09/21
16:36
09/21/17
16:36
General news
Fed Balance Sheet Level data reported »

Week of 9/20 Fed Balance…

TXN

Texas Instruments

$86.05

0.22 (0.26%)

16:35
09/21/17
09/21
16:35
09/21/17
16:35
Hot Stocks
Texas Instruments raises dividend 24%, adds to repurchase program »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

16:34
09/21/17
09/21
16:34
09/21/17
16:34
Hot Stocks
Versartis' somavaratan did not meet primary endpoint in Phase 3 trial »

Versartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$90.44

-1.51 (-1.64%)

, DWDP

DowDuPont

$70.32

-0.09 (-0.13%)

16:34
09/21/17
09/21
16:34
09/21/17
16:34
Hot Stocks
FMC Corporation cleared for proposed acquisition of DuPont Crop Protection unit »

FMC Corporation (FMC)…

FMC

FMC Corporation

$90.44

-1.51 (-1.64%)

DWDP

DowDuPont

$70.32

-0.09 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

MCD

McDonald's

$159.03

-0.85 (-0.53%)

16:32
09/21/17
09/21
16:32
09/21/17
16:32
Hot Stocks
McDonald's increases quarterly dividend 7% »

McDonald's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

16:30
09/21/17
09/21
16:30
09/21/17
16:30
Options
Preliminary option volume of 13.2M today »

Preliminary option volume…

TGI

Triumph Group

$27.85

-0.2 (-0.71%)

, BA

Boeing

$256.04

0.58 (0.23%)

16:27
09/21/17
09/21
16:27
09/21/17
16:27
Hot Stocks
Triumph Group signs contract extensions with Boeing for ducting, floor panels »

Triumph Group (TGI)…

TGI

Triumph Group

$27.85

-0.2 (-0.71%)

BA

Boeing

$256.04

0.58 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

16:25
09/21/17
09/21
16:25
09/21/17
16:25
Earnings
YogaWorks sees Q3 revenue $12.7M-$13.2M, consensus $12.9M »

For the third quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

VSAR

Versartis

$21.60

-0.25 (-1.14%)

16:25
09/21/17
09/21
16:25
09/21/17
16:25
Hot Stocks
Breaking Hot Stocks news story on Versartis »

Versartis trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

16:22
09/21/17
09/21
16:22
09/21/17
16:22
Earnings
YogaWorks reports Q2 adjusted net loss $3.1M vs. adjusted net loss $2.7M in Q216 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

CSII

Cardiovascular Systems

$27.63

0.38 (1.39%)

16:20
09/21/17
09/21
16:20
09/21/17
16:20
Initiation
Cardiovascular Systems initiated  »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
09/21/17
09/21
16:20
09/21/17
16:20
Options
Closing CBOE SPX and VIX Index summary for September 21st »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.